Sinovac’s COVID-19 shot effective in Brazil trials

 

• Sinovac Biotech's (NASDAQ:SVA) coronavirus vaccine has passed the 50% threshold for efficacy in late-stage trials in Brazil, WSJ reports.
• Considering these results, regulators can give it the green light for use, said people involved in its development.
• Brazil is the first country to complete Phase 3 trials of the China's CoronaVac vaccine, which is also being tested in Indonesia and Turkey.
• The results showed CoronaVac with an effective rate above 50%, the threshold for a vaccine to be considered viable by international scientists. No further information was provided.
• As wealthy nations buy up doses of vaccines from Western drugmakers, poorer countries have pinned their hopes on China.
• Sinovac’s CoronaVac vaccine can also be kept in a standard refrigerator at between about 36 and 46 degrees Fahrenheit, making it easier to transport and store.
• The results of the trials will be submitted to drug regulators in both Brazil and China on Wednesday.
• https://seekingalpha.com/news/3646499-sinovac-s-covidminus-19-shot-effective-in-brazil-trials-wsj